CGTX Shares Rise Amid FDA Alignment on Phase 3 Alzheimer's Drug Pathway

Cognition Therapeutics shares are trading higher after the company received confirmation from the U.S. FDA regarding the Phase 3 program design for zervimesine in Alzheimer's disease, supporting a potential New Drug Application filing.